Your browser is no longer supported. Please, upgrade your browser.
Settings
MRSN Mersana Therapeutics, Inc. daily Stock Chart
MRSN [NASD]
Mersana Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.98 Insider Own- Shs Outstand50.39M Perf Week15.16%
Market Cap443.94M Forward P/E- EPS next Y-1.52 Insider Trans- Shs Float46.87M Perf Month14.86%
Income-34.40M PEG- EPS next Q-0.38 Inst Own77.30% Short Float4.87% Perf Quarter238.85%
Sales43.30M P/S10.25 EPS this Y-64.10% Inst Trans-6.95% Short Ratio5.45 Perf Half Y220.36%
Book/sh1.95 P/B4.52 EPS next Y-139.70% ROA-28.10% Target Price11.25 Perf Year24.44%
Cash/sh2.22 P/C3.96 EPS next 5Y- ROE-41.10% 52W Range1.32 - 9.40 Perf YTD53.75%
Dividend- P/FCF- EPS past 5Y- ROI-746.10% 52W High-6.28% Beta-
Dividend %- Quick Ratio5.10 Sales past 5Y- Gross Margin- 52W Low567.42% ATR0.75
Employees86 Current Ratio5.10 Sales Q/Q-63.60% Oper. Margin-84.20% RSI (14)63.50 Volatility8.29% 9.27%
OptionableYes Debt/Eq0.06 EPS Q/Q52.40% Profit Margin-79.50% Rel Volume1.29 Prev Close9.27
ShortableYes LT Debt/Eq0.05 EarningsFeb 28 BMO Payout- Avg Volume418.52K Price8.81
Recom1.80 SMA2015.46% SMA5040.40% SMA200123.55% Volume538,348 Change-4.96%
Jan-21-20Reiterated H.C. Wainwright Buy $7 → $12
Mar-11-19Downgrade JP Morgan Neutral → Underweight
Nov-14-18Upgrade Leerink Partners Mkt Perform → Outperform
May-08-18Initiated Robert W. Baird Outperform
Mar-19-18Downgrade JP Morgan Overweight → Neutral
Feb-21-20 08:00AM  Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2019 Financial Results and Business Updates GlobeNewswire
Feb-18-20 08:00AM  Mersana Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire +9.10%
Jan-21-20 08:57AM  Mersana Therapeutics (MRSN) Looks Good: Stock Adds 5.8% in Session Zacks
Jan-10-20 08:00AM  Mersana Therapeutics Announces Pipeline Updates and 2020 Strategic Priorities and Milestones GlobeNewswire
Jan-02-20 08:00AM  Mersana Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire -6.46%
Dec-13-19 01:54PM  Hedge Funds Overwhelmingly Bullish About Mersana Therapeutics, Inc. (MRSN) Anymore Insider Monkey
Dec-06-19 09:47AM  Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment? Simply Wall St.
Nov-08-19 08:00AM  Mersana Therapeutics Presents New Preclinical Data from Immunosynthen Platform at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting GlobeNewswire +5.05%
Nov-06-19 06:00AM  Mersana Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Updates GlobeNewswire +7.03%
Oct-30-19 08:00AM  Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2019 Financial Results and Business Updates GlobeNewswire -5.41%
Oct-11-19 12:44PM  What Type Of Shareholder Owns Mersana Therapeutics, Inc.'s (NASDAQ:MRSN)? Simply Wall St. -6.25%
Sep-27-19 08:00AM  Mersana Therapeutics to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Aug-28-19 08:00AM  Mersana Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-20-19 08:00AM  Mersana Therapeutics Announces Initiation of Expansion Study of XMT-1536 in Patients with Platinum-Resistant Ovarian Cancer and Non-Small Cell Lung Cancer GlobeNewswire
Aug-12-19 03:43PM  Calculating The Intrinsic Value Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Simply Wall St. -9.32%
Aug-08-19 06:00AM  Mersana Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Updates GlobeNewswire
Aug-06-19 08:00AM  Mersana Therapeutics to Present at the Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-01-19 08:00AM  Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2019 Financial Results and Business Updates GlobeNewswire
Jul-05-19 12:29PM  Hedge Funds Have Never Been This Bullish On Mersana Therapeutics, Inc. (MRSN) Insider Monkey
Jul-04-19 12:07PM  Does Mersana Therapeutics, Inc. (NASDAQ:MRSN) Have A Particularly Volatile Share Price? Simply Wall St.
Jun-12-19 08:00AM  Mersana Therapeutics Announces Appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy GlobeNewswire
Jun-01-19 09:00AM  Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-30-19 08:00AM  Mersana Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-20-19 08:00AM  Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-16-19 11:14PM  Mersana Therapeutics, Inc. (MRSN) Q1 2019 Earnings Call Transcript Motley Fool -16.33%
May-09-19 06:00AM  Mersana Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Updates GlobeNewswire +5.54%
May-02-19 08:00AM  Mersana Therapeutics to Host Conference Call Announcing First Quarter 2019 Financial Results and Business Updates GlobeNewswire -5.34%
Apr-29-19 01:25PM  Consider These 3 Falling Knives GuruFocus.com +8.32%
Apr-09-19 08:15AM  New Research: Key Drivers of Growth for Liberty Global, KKR Real Estate Finance Trust, AGCO, Model N, STAAR Surgical, and Mersana Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -6.26%
Apr-01-19 08:00AM  Mersana Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-25-19 08:00AM  Mersana Therapeutics Announces Poster and Presentation at the American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
Mar-12-19 11:02AM  What Should You Know About Mersana Therapeutics, Inc.s (NASDAQ:MRSN) Earnings Trajectory? Simply Wall St. +16.86%
Mar-11-19 02:33PM  JPMorgan Downgrades Mersana, Says Data Readouts Unlikely To Reverse Street Sentiment Benzinga
Mar-08-19 06:00AM  Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates GlobeNewswire +7.11%
Mar-06-19 08:00AM  Mersana Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference GlobeNewswire -6.81%
Mar-05-19 04:01PM  Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Mar-01-19 04:01PM  Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2018 Financial Results and Business Updates GlobeNewswire -14.52%
08:50AM  The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis Benzinga
07:00AM  Mersana Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Feb-28-19 04:03PM  Mersana Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire -20.14%
Feb-20-19 08:00AM  Mersana Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-10-19 06:52AM  Mersana CEO details path forward after breakup with Takeda American City Business Journals
Jan-04-19 02:07PM  Are Mersana Therapeutics, Inc.s (NASDAQ:MRSN) Interest Costs Too High? Simply Wall St.
07:13AM  Mersana to discontinue development of one cancer treatment to focus on another MarketWatch
07:00AM  Mersana Therapeutics Announces Strategic Priorities and Goals for 2019 and Beyond GlobeNewswire
Jan-02-19 08:00AM  Mersana Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire +5.64%
Nov-28-18 08:25AM  New Research: Key Drivers of Growth for Mersana Therapeutics, Maiden, Payment Data, CareDx, Natera, and Spero Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -7.53%
Nov-27-18 08:00AM  Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer GlobeNewswire
Nov-13-18 07:00AM  Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates GlobeNewswire
Nov-12-18 09:00AM  Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer GlobeNewswire
07:00AM  Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018 GlobeNewswire
Nov-08-18 05:00PM  Mersana Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference GlobeNewswire
Nov-06-18 05:00PM  Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2018 Financial Results and Business Updates GlobeNewswire
Oct-17-18 09:15AM  Analysis: Positioning to Benefit within Matrix Service, Mersana Therapeutics, Quorum Health, Canopy Growth, Bristow Group, and Menlo Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Sep-26-18 04:03PM  Mersana Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-25-18 08:00AM  Mersana Therapeutics Presents New Preclinical Data on XMT-1536 at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer GlobeNewswire
Sep-17-18 04:34PM  Why Nio, Mersana Therapeutics, and Tandem Diabetes Care Slumped Today Motley Fool -22.53%
10:52AM  FDA lifts partial hold on Mersana cancer drug trial, but shares fall American City Business Journals
07:34AM  UPDATE: Mersana Therapeutics stock leaps 4.7% after FDA lifts clinical hold on cancer therapy trial MarketWatch
07:00AM  Mersana Announces FDA Lifts Partial Clinical Hold for XMT-1522 GlobeNewswire
Aug-30-18 04:01PM  Mersana Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-23-18 07:50AM  New Research Coverage Highlights Live Nation Entertainment, LightPath Technologies, Synchronoss Technologies, Mallinckrodt public limited company, Capricor Therapeutics, and Mersana Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-15-18 09:49AM  Mersana Therapeutics, Inc. (MRSN) Q2 2018 Earnings Conference Call Transcript Motley Fool
06:00AM  Mersana Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-14-18 04:20PM  Mersana Therapeutics Announces Second Quarter 2018 Financial Results and Provides Business Updates GlobeNewswire
Aug-08-18 04:03PM  Mersana Therapeutics to Present at the Wedbush PacGrow Healthcare Conference GlobeNewswire
04:01PM  Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2018 Financial Results and Business Updates GlobeNewswire
Jul-19-18 08:37AM  Mersana Therapeutics shares plummet 40% after patient death in cancer trial MarketWatch -31.59%
08:36AM  Mersana's cancer drug trial put on hold by FDA; shares halted Reuters
08:12AM  Mersana Therapeutics cancer drug trial on partial hold by FDA Reuters
08:00AM  Mersana Therapeutics Announces Partial Clinical Hold for XMT-1522 Clinical Trial GlobeNewswire
Jun-14-18 07:45AM  Investor Expectations to Drive Momentum within The Kroger, Mohawk Industries, Mersana Therapeutics, Riot Blockchain, Snap, and The Sherwin-Williams Discovering Underlying Factors of Influence GlobeNewswire
Jun-04-18 09:01AM  Mersana Presents Interim Dose-Escalation Data on XMT-1522 in Select Cancers at ASCO 2018 GlobeNewswire -23.00%
May-31-18 04:01PM  Mersana Therapeutics to Present at the Jefferies Global Healthcare Conference GlobeNewswire
May-22-18 04:01PM  Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1522 at the 2018 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-14-18 04:01PM  Mersana Therapeutics Announces First Quarter 2018 Financial Results and Provides Business Updates GlobeNewswire
May-08-18 12:01PM  Baird: Mersana Is A Buy On Differentiated Platform For Cancer Indications Benzinga
May-07-18 04:01PM  Mersana Therapeutics to Host Conference Call Announcing First Quarter 2018 Financial Results and Business Updates GlobeNewswire
May-01-18 04:01PM  Mersana Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire
Apr-24-18 07:40AM  Wired News European Medicines Agency Granted Orphan Drug Designation for Abeonas ABO-202 Gene Therapy Program in Batten Disease ACCESSWIRE -5.88%
Apr-23-18 07:00AM  Wired News - Krystal Biotech's Lead Product Candidate, KB103, for Treatment of DEB Receives Orphan Medicinal Product Designation in Europe ACCESSWIRE
Apr-17-18 01:01PM  Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018 GlobeNewswire
Apr-09-18 08:00AM  Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the American Association for Cancer Research Annual Meeting 2018 GlobeNewswire +7.21%
Apr-03-18 05:43PM  Mersana Therapeutics Incs (NASDAQ:MRSN) Profit Outlook Simply Wall St. -9.16%
Mar-28-18 07:30AM  Mersana Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates GlobeNewswire -8.03%
Mar-26-18 07:58PM  Does Mersana Therapeutics Incs (NASDAQ:MRSN) Past Performance Indicate A Weaker Future? Simply Wall St.
Mar-21-18 04:01PM  Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Full Year 2017 Financial Results and Business Updates GlobeNewswire
Mar-19-18 12:45PM  Eeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In Portfolio Rebalancing Benzinga
08:00AM  Mersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen GlobeNewswire
Mar-12-18 08:00AM  Mersana Appoints David A. Spellman as Chief Financial Officer GlobeNewswire
Mar-07-18 08:38AM  Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season? Zacks
Feb-07-18 08:00AM  Mersana Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Jan-08-18 08:00AM  Mersana Therapeutics Outlines 2017 Milestones and 2018 Goals GlobeNewswire
Dec-28-17 07:18AM  Mersana Therapeutics, Inc. is trading above its 50 day moving average : MRSN-US : December 28, 2017 Capital Cube
Dec-20-17 04:01PM  Mersana Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-15-17 08:00AM  Mersana Therapeutics Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-12-17 08:00AM  Mersana Announces First Patient Dosed with XMT-1536 in Phase 1 Study in Patients with NaPi2b-Expressing Tumors GlobeNewswire
Dec-04-17 01:20PM  Mersana Therapeutics Inc (MRSN): Earnings Expected To Remain Subdued Simply Wall St.
Nov-24-17 11:27AM  Mersana Therapeutics, Inc. Value Analysis (NASDAQ:MRSN) : November 24, 2017 Capital Cube
Nov-22-17 07:29AM  Mersana Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MRSN-US : November 22, 2017 Capital Cube
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.